Skip to content

GREENVEIL

  • pharma

Crospovidone

CAS 9003-39-8

Concern score

Not assessed — no hazard data yet.

Crospovidone in plain language

What it is

Also known as Unspecified crospovidone · 1-ETHENYL-2-PYRROLIDINONE, homopolymer · 1-Vinyl-2-pyrrolidinone homopolymer · PVP, crosslinked-

What it does

We don't have a plain-language description for Crospovidone yet.

Is it a concern?
We haven't assessed a concern score for this ingredient yet.

Regulation

No restrictions found. Crospovidone appears in these published regulatory listings.

  • Inactive ingredient in US drugs
  • USFDAinactive ingredient database33 entries — 8 administration routes
    • Route: INTRAVENOUS; Dosage form: INJECTION; Potency: 1.4 mgSource →
    • Route: OPHTHALMIC; Dosage form: SOLUTION; Potency: 3 %w/wSource →
    • Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 250 mgSource →
    • Route: ORAL; Dosage form: CAPSULE, COATED, EXTENDED RELEASE; Potency: NASource →
    • Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE; Maximum daily exposure: 365 mgSource →
    • Route: ORAL; Dosage form: CAPSULE, EXTENDED RELEASE; Potency: 25.1 mgSource →
    • Route: ORAL; Dosage form: GRANULE; Maximum daily exposure: 238 mgSource →
    • Route: ORAL; Dosage form: GRANULE, FOR SOLUTION; Potency: 36.3 mg/120mlSource →
    • Route: ORAL; Dosage form: GRANULE, FOR SUSPENSION; Maximum daily exposure: 810 mgSource →
    • Route: ORAL; Dosage form: PELLET; Maximum daily exposure: 28 mgSource →
    • Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 114 mgSource →
    • Route: ORAL; Dosage form: SUSPENSION, EXTENDED RELEASE; Potency: 186.8 mgSource →
    • Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 2352 mgSource →
    • Route: ORAL; Dosage form: TABLET, CHEWABLE; Maximum daily exposure: 300 mgSource →
    • Route: ORAL; Dosage form: TABLET, CHEWABLE, EXTENDED RELEASE; Maximum daily exposure: 90 mgSource →
    • Route: ORAL; Dosage form: TABLET, COATED; Maximum daily exposure: 208 mgSource →
    • Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Maximum daily exposure: 336 mgSource →
    • Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 624 mgSource →
    • Route: ORAL; Dosage form: TABLET, FILM COATED; Maximum daily exposure: 787 mgSource →
    • Route: ORAL; Dosage form: TABLET, FILM COATED, EXTENDED RELEASE; Maximum daily exposure: 24 mgSource →
    • Route: ORAL; Dosage form: TABLET, FOR SUSPENSION; Maximum daily exposure: 1733 mgSource →
    • Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 1260 mgSource →
    • Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; Maximum daily exposure: 660 mgSource →
    • Route: ORAL; Dosage form: WAFER; Potency: 97 mgSource →
    • Route: SUBCUTANEOUS; Dosage form: PELLET; Potency: 2 mgSource →
    • Route: SUBLINGUAL; Dosage form: TABLET; Maximum daily exposure: 60 mgSource →
    • Route: TOPICAL; Dosage form: EMULSION; Potency: 1 %w/wSource →
    • Route: TOPICAL; Dosage form: LOTION; Potency: 0.5 %w/wSource →
    • Route: TRANSDERMAL; Dosage form: FILM; Maximum daily exposure: 4 mgSource →
    • Route: TRANSDERMAL; Dosage form: FILM, EXTENDED RELEASE; Maximum daily exposure: 60 mgSource →
    • Route: TRANSDERMAL; Dosage form: SYSTEM; Maximum daily exposure: 286 mgSource →
    • Route: VAGINAL; Dosage form: AEROSOL, FOAM; Potency: 1 %w/wSource →
    • Route: VAGINAL; Dosage form: SUPPOSITORY; Potency: 116.1 mgSource →
  • USFDAlisted in openFDA substanceopenFDA substance registry classifies this ingredient as mixture.
    • openFDA substance registry classifies this ingredient as mixture.Source →

Evidence & sources

No graded research studies for Crospovidone yet. This record is compiled from the published data sources below — registries and regulatory listings, not study findings.

3 data sources

Where this comes from

  • FDA Inactive Ingredient Database

    regulatory · updated 2026-01-09

    Open →

  • FDA GSRS UNII

    registry · updated 2026-02-26

    Open →

  • openFDA Substance

    registry · updated 2026-05-24

    Open →

Suitability

Context-specific fit derived from published classifications and the current ingredient evidence profile.

Fragrance avoidance

Nothing to weigh for this context yet.

No signal in this context

We have no published hazard signal for this ingredient, so we cannot say how it behaves in this context — that is missing evidence, not a clean result.

Catalog

Found in these products

Their ingredient lists include Crospovidone; each product's own rating depends on its whole formula, so it is shown on the product page, not here.

See all 7 →Find products without it →